SCANCELL
Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. It has facilities in San Diego, Oxford and Nottingham and is listed on AIM.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial showed that SCIB1, when used as monotherapy, produced a highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.
Pre-clinical data on combining ImmunoBody® with checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) has shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone. A randomised Phase 2b study to evaluate the effects of adding SCIB1 to a checkpoint inhibitor on response rate in late stage melanoma patients will commence in the US in 2017.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The lead product from the Moditope® platform, Modi-1, is expected to enter clinical trials in breast and ovarian cancer and osteosarcoma in 2017.
